文献速递炎症性肠病

上皮中性粒细胞浸润早期变化预测溃疡性结肠炎生物制剂长期应答

Early Change in Epithelial Neutrophilic Infiltrate Predicts Long-Term Response to Biologics in Ulcerative Colitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-07-03

该研究对VARSITY试验中734例有组织学数据的溃疡性结肠炎患者进行事后分析,评估基线至第14周组织学评分及亚成分变化对第52周内镜改善(EI)和组织内镜黏膜改善(HEMI)的预测价值。结果显示上皮中性粒细胞浸润变化预测效能最佳,是唯一独立预测因子。

要点

  • 上皮中性粒细胞浸润从基线至第14周的变化对第52周EI和HEMI预测AUC分别为0.83和0.85。
  • 多因素分析中上皮中性粒细胞改善是唯一与第52周EI和HEMI几率增加相关的组织学参数。
  • 第14周中性粒细胞累及超过50%隐窝者,无论第14周Mayo内镜评分如何,第52周HEMI达成率均显著更低。

核心结论

  • 诱导治疗后上皮中性粒细胞浸润是维持期EI或HEMI达成的唯一独立预测因子,有助于按生物制剂应答可能性对患者分层。

研究设计与样本

  • VARSITY试验事后分析,纳入734例有组织学数据的溃疡性结肠炎患者。
  • 采用ROC曲线和多因素逻辑回归分析基线及第14周Robarts组织病理指数、Geboes评分、各组织学亚成分及基线疾病特征对第52周EI和HEMI的预测价值。

主要发现

  • 上皮中性粒细胞受累从基线至第14周的变化预测第52周EI的AUC为0.83(95%CI 0.74-0.91),预测HEMI的AUC为0.85(95%CI 0.76-0.94)。

临床怎么用

  • 可依据诱导治疗后上皮中性粒细胞浸润变化评估溃疡性结肠炎患者生物制剂维持治疗应答可能性。
  • 第14周中性粒细胞累及超过50%隐窝提示第52周HEMI达成可能性低, irrespective of 第14周Mayo内镜评分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The prognostic value of histologic scores, grades, and individual histologic subcomponents, alone or in combination with endoscopy, for predicting endoscopic improvement (EI) and histoendoscopic mucosal improvement (HEMI) during maintenance therapy in ulcerative colitis remains uncertain. METHODS: We performed a post hoc analysis of participants from the VARSITY trial (n = 734 with histology). Receiver operating characteristic and multivariate logistic regression analyses were performed to assess whether baseline and/or week 14 assessments for the Robarts Histopathology Index, Geboes score, individual histologic subcomponents, and baseline disease characteristics, including endoscopic severity and biomarkers, could predict the achievement of EI and HEMI at week 52. RESULTS: Changes in epithelial neutrophil involvement from baseline to week 14 had the best performance for predicting week 52 EI (area under the curve, 0.83; 95 % confidence interval [CI], 0.74-0.91) and HEMI (area under the curve, 0.85; 95 % CI, 0.76-0.94). On multivariate analyses, improvement of neutrophils in the epithelium was the only histologic parameter associated with increased odds of week 52 EI (odds ratio, 3.63; 95 % CI, 1.45-9.08; P = .0059) and HEMI (odds ratio, 6.88; 95 % CI, 3.29-14.36; P < .0001). Patients with more than 50 % of crypts involved with neutrophils at week 14 were significantly less likely to achieve week 52 HEMI irrespective of week 14 Mayo endoscopic scores (week 14 Mayo endoscopic score of 2-3: 9.9 % vs 22.4 %; P = .001; week 14 Mayo endoscopic score of 0-1: 33 % vs 62.4 %; P = .044). CONCLUSIONS: Our results on epithelial neutrophilic infiltrate after induction therapy as the only independent predictor for achievement of maintenance EI or HEMI helps clarify the clinical relevance of measuring histologic disease activity in ulcerative colitis. Epithelial neutrophilic infiltrate poses a means to stratify patients according to their likelihood of response to biologic treatment.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Narula N, Wong ECL, Colombel JF, et al. Early Change in Epithelial Neutrophilic Infiltrate Predicts Long-Term Response to Biologics in Ulcerative Colitis. Clin Gastroenterol Hepatol. 2021. PMID: 34229037. doi:10.1016/j.cgh.2021.07.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。